‹

News & Bulletin UpdatesNews

INDIA DOMESTIC PRICES – WHAT IS GOING ON?

Isobutanol surges Rs 7 in Kandla as fortnightly gains reach Rs 25.50 – India Domestic Prices – What Is Going On?

IndianPetroChem

This edition covers:

  • Isobutanol surges Rs 7 in Kandla as fortnightly gains reach Rs 25.50
  • Propionic alcohol rebounds Rs 5.50 weekly but remains below monthly benchmark levels
  • LAB edges higher in Kandla but remains sharply below monthly benchmark levels
  • Mono chloro benzene slides Rs 3.50 as weekly selling pressure intensifies further
  • Acetone climbs Rs 5 in Delhi as quarterly recovery gathers fresh momentum
  • BDO slips Rs 3 in Ahmedabad as three-month decline reaches Rs 18
  • POP polyether edges higher weekly but three-month price weakness remains firmly intact
  • Liquid alkali sinks Rs 25 monthly as Delhi prices test support level
  • BPA extends Mumbai decline as monthly losses deepen to Rs 10
  • BDGE plunges Rs 20 weekly as fortnightly losses deepen to Rs 55
  • PEG falls Rs 4 as three-month decline reaches Rs 30 in Ahmedabad
  • PAM stabilises near Ahmedabad lows after monthly decline reaches Rs 18
  • Acrylonitrile jumps Rs 20 weekly as domestic prices stage powerful recovery
  • Acetic acid gains Rs 5 as Hazira rebound reaches Rs 13 fortnightly
  • DINP slips Rs 2 weekly but remains above last month's price level
  • DIBP climbs Rs 2 weekly as Mumbai monthly gains reach Rs 9
  • DOTP surges Rs 13 in Delhi as prices approach recent resistance level
  • Spirodiclofen slides Rs 30 weekly as three-month decline reaches Rs 250
  • POM reaches one-year high as Ahmedabad prices extend steady monthly rally
  • PA6 holds steady weekly but Ahmedabad monthly decline reaches Rs 12
  • PA66 holds flat in Ahmedabad while six-month price weakness remains intact
  • PU stays unchanged in Ahmedabad as market settles into balanced trading range
  • RSS slides Rs 5 as Mumbai market opens September at monthly low

The complete bulletin is available to subscribers.

Read the complete bulletin

Request a free trial and our team will set up your access. Subscribers log in and return to this bulletin in full.

Questions about access? Contact our team
← Browse more news & analysis